Immuno-oncology
At Abcam, we have a strong immuno-oncology focus and are constantly developing new reagents as solutions for your research.
Browse below to find out more.
Immuno-oncology at Abcam
Immuno-oncology has revolutionized cancer treatment by harnessing the body’s own immune system to treat diseases with immunotherapies. From target discovery to IVD or clinical phase analysis, we can support you at every stage of your IO research with the right products for your needs. To ensure the best performance when possible, we test and validate our products in the most relevant models in both healthy and diseased tissue and assays.
Our dedicated IO team is focused on identifying and prioritizing the most relevant targets in our pipeline for cutting-edge assay solutions.
Click on each area to discover more:
Immune checkpoints | Immune response | Tumor response/immune evasion | Multiplex imaging | Work with us
Immune checkpoints
Immune checkpoints act as regulators of the immune system to maintain homeostasis and prevent autoimmunity.
New and emerging immune checkpoints targets offer the potential for increased accuracy in diagnosis, patient stratification, and improved immunotherapies. Our range of antibodies allows you to research all the latest targets in the field.
At Abcam, we are committed to bringing you the best immune checkpoint antibodies for research and assay development to progress your breakthrough.
Advance immuno-oncology research, together.
We collaborate with top scientists around the world to deliver to you the most comprehensive reagents pipeline for immuno-oncology.
Interested in working with us or want to hear more?
Contact us at immuno.oncology@abcam.com.
Immune response
As part of the adaptive immune response, activated T cells recognize and destroy cancer cells. These cells are activated via dendritic cells that serve to stimulate the T-cell receptor (TCR) in mature T cells with cognate antigen-MHC complexes in parallel with additional costimulatory checkpoint signals.
Activation of other immune cells, such as NK cells and dendritic cells, also plays a key role in modulating the tumor-specific immune response.
Choose the best immune cell markers for your research
Tumor response/Immune evasion
Cancer cells employ several immunosuppressive mechanisms to prevent the protective function of the immune system. For example, by downregulating tumor antigen expression on their surface, cancer cells can evade subsequent recognition.
Antigens, such as the Major Histocompatibility Complex (MHC) proteins or costimulatory molecules, can also be downregulated to impair antigen presentation. Expression of resistance molecules, such as STAT3, may be increased by cancer cells, leading to impaired maturation of antigen-presenting cells, such as dendritic cells.
View the latest resources and reagents for immune evasion
Find resources and tools for understanding tumor-specific response and resistance to cancer immunotherapies
Multiplex imaging to investigate the tumor microenvironment
Confidently build antibody panels to interrogate the tumor microenvironment in multiplex using an expanding catalog of immuno-oncology focused clones. Whichever multiplex technique or technology you choose, our recombinant monoclonal rabbit antibodies are available in the right formats to maximize your success. Read more here.
We’d love to hear from you
If you would like to speak to our team about how we can support your research with our tailored solutions, connect with us immuno.oncology@abcam.com.